The Truth About GLP-1 Titration: What You Need to Know
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Avoid GLP-1 Side Effects: Why Wegovy/Zepbound Titration Matters (Dr. Kulmeet Kundlas) Dr. Kulmeet Kundlas, a primary care physician of 30+ years, explains that many severe GLP-1 agonist side effects from Wegovy, Zepbound/Mounjaro (tirzepatide), and related medications are often due to titration errors, patient impatience, pharmacy/education gaps, or restarting at too high a dose after missed injections. He describes how GLP-1s disrupt GI motility, citing Wegovy trial rates of nausea (40%) and vomiting (26%), and outlines the rigid step-up schedules (Wegovy starting at 0.25 mg weekly for 4 weeks toward a 2.4 mg maintenance dose; tirzepatide starting at 2.5 mg with increases every 4 weeks). He warns against unsafe dose-jumping and using non–FDA-approved compounding sources, notes pancreatitis warning signs, and emphasizes physician/pharmacist training plus lifestyle measures like high-protein diet, exercise, sleep, and stress management. 00:00 GLP-1 Side Effects Explained 01:15 Why the First Dose Hits Hard 02:29 Real Results and Big Picture 03:30 Wegovy Titration and Stacking 05:35 Zepbound Dosing and Missed Shots 06:00 Pen Mistakes and Compounding Risks 07:31 Warning Signs and Safe Wrap-Up